Dr. Ir. Jeroen de Vrij
CEO
About Us
OUR COMPANY
ExoVectory is a biotechnology company developing exosomes as a next-generation delivery platform for gene therapeutics. Founded in 2020 as a spin-out from Erasmus MC, The Netherlands, we are headquartered at Leiden Bio Science Park and collaborate with world-leading academic and industry partners including LUMC, UMC Utrecht and Thermo Fisher Scientific. Since our founding, we have built a strong foundation, growing our team, protecting our intellectual property, generating proof-of-concept data, and securing over €3 million in non-dilutive funding.
Our mission is to transform exosomes into precision delivery vehicles for next-generation genetic therapies targeting life-threatening and currently untreatable diseases.
leadership team
Mr. Drs. Ernst Ligthart
Legal & Finance
Dr. Wouter W. Woud
Lead Technology Officer
Cees Juffermans
Business Development
Advisory & Key Partners
Business Strategy
- Dr. Bram BoutFormer CruCell, BioCeros, current JJP Biologics
- Dr. Inez de Greef3D-PharmXchange, Treeway
- Dr. Audrey SporrijBioNTech, Clearview, Vida Ventures
Science / Medical
- Prof. Marie-José GoumansLUMC, Cardiovascular
- Prof. Mirjam HeemskerkLUMC, T-cell therapy, Oncology
- Prof. Clemens DirvenErasmus MC, Oncology-Neuro
- Dr. Koen BreyneHarvard, Gene Therapy
VISION & IMPACT BROCHURE
Want the full picture? Our Vision & Impact Brochure covers ExoVectory's founding story, the diseases we are targeting and why we chose them, and our vision for what exosome medicine can achieve.
DOWNLOAD BROCHURE